Table 2 Clinical and pathological features of head and neck squamous cell carcinoma patients.
From: SOX2 activation predicts prognosis in patients with head and neck squamous cell carcinoma
TCGA cohort (N = 513) | Leipzig cohort (N = 270) | FHCRC cohort (N = 97) | |
|---|---|---|---|
Gender | |||
Male | 370 (73.7%) | 223 (82.6%) | 66 (68.0%) |
Female | 132 (26.3%) | 47 (17.4%) | 31 (32.0%) |
Age (mean ± SD) | 60.9 ± 11.9 | 60.1 ± 10.0 | NA |
Anatomic site | |||
Oral cavity | 301 (60.0%) | 83 (30.7%) | 86 (88.7%) |
Oropharynx | 79 (15.7%) | 102 (37.8%) | 11 (11.3%) |
Larynx | 113 (22.5%) | 48 (17.8%) | 0 |
Hypopharynx | 9 (1.8%) | 33 (12.2%) | 0 |
others | 0 | 4 (1.5%) | 0 |
Primary tumor | |||
T1 | 33 (6.8%) | 35 (13.0%) | NA |
T2 | 147 (30.2%) | 80 (29.6%) | NA |
T3 | 129 (26.5%) | 58 (21.5%) | NA |
T4 | 178 (36.6%) | 97 (35.9%) | NA |
Regional lymph node | |||
N0 | 238 (49.5%) | 94 (34.8%) | NA |
N1 | 79 (16.4%) | 32 (11.9%) | NA |
N2 | 155 (32.2%) | 132 (48.9%) | NA |
N3 | 9 (1.9%) | 12 (4.4%) | NA |
Stage | |||
I | 20 (4.1%) | 18 (6.7%) | 30 (30.9%) |
II | 96 (19.6%) | 37 (13.7%) | 11 (11.3%) |
III | 101 (20.7%) | 37 (13.7%) | 15 (15.5%) |
IV | 272 (55.6%) | 178 (65.9%) | 41 (42.3%) |
HPV status | |||
Positive | 68 (19.9%) | 60 (23.4%) | 0 |
Negative | 274 (80.1%) | 196 (76.6%) | 97 (100%) |
Tobacco use | |||
Never | 114 (23.3%) | 48 (17.8%) | NA |
Yes | 376 (76.7%) | 222 (82.2%) | NA |
Alcohol use | |||
Never | 154 (42.1%) | 31 (11.5%) | NA |
Yes | 212 (57.9%) | 239 (88.5%) | NA |
SOX2 signature | |||
SOX2-high | 227 (44.2%) | 146 (54.1%) | 55 (56.7%) |
SOX2-low | 286 (55.8%) | 124 (45.9%) | 42 (43.3%) |
